Incidence of epiretinal membrane formation following treatment of diabetic retinopathy with panretinal photocoagulation therapy
Year: 2025
Type: article
Study design: Observational Study
Abstract: AIM: To report the incidence of epiretinal membrane (ERM) formation following panretinal photocoagulation (PRP) as the treatment for diabetic retinopathy (DR). METHODS: Retrospective cross-sectional study of patient charts between January 1st, 2010 to January 1st, 2017 with at least 1y follow-up data. All 809 patients treated with PRP for DR were evaluated for exclusion criteria and 73 eyes remained after exclusion for confounding variables related to ERM formation such as other procedures or diseases. Outcomes were determined through medical record review and masked review of optical coherence tomography (OCT) images. Cohen’s kappa was completed to determine if there was an agreement between masked retinal specialists on OCT evaluations. Univariate logistic regression was used to determine the unadjusted odds ratio for patient and procedural characteristics on the formation of ERMs. Multiple logistic regression was then completed on select variables that met the cutoff of 0.25 for a statistically significant contribution by the Wald test with the sequential addition of clinical variables that contributed positively to the model. RESULTS: Among the 73 eyes studied, 9.6% formed an ERM with an average time to formation of 1.4y. The minimum power uses during PRP was found to be statistically significant between non-ERM formers and ERM formers (P=0.044). When adjusting for all selected variables aside from minimum power used, multiple logistic regression determined that for every 10 mW increase in minimum power used during PRP, there is an increase in log odds of 1.009 (SE: 0.003, P=0.014). CONCLUSION: The incidence of ERM formation in 2y following treatment of DR with PRP is roughly 1 in every 10 eyes treated.
Language: English
Subfield: Ophthalmology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $1,800
Funders: Howard Hughes Medical Institute, Barth Syndrome Foundation, Pfizer, Michigan Economic Development Corporation, Fondation Motrice, Louisiana State University, Oklahoma Medical Research Foundation, Sidaction, Pakistan Science Foundation, Japan Agency for Medical Research and Development, Consorzio Interuniversitario Biotecnologie, Hermann und Lilly Schilling-Stiftung für Medizinische Forschung, Amorepacific Corporation, Triad Foundation, Department of Science and Technology, Ministry of Science and Technology, India, Council of Scientific and Industrial Research, India, Deutsche Forschungsgemeinschaft, Agence Nationale de la Recherche, National Natural Science Foundation of China, Grantová Agentura České Republiky, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Bundesministerium für Bildung und Forschung, Cancerfonden, China Postdoctoral Science Foundation, Deutsches Zentrum für Luft- und Raumfahrt, Forschungszentrum Jülich, Ministero della Salute, Nederlandse Organisatie voor Wetenschappelijk Onderzoek, Agence Nationale de Recherches sur le Sida et les Hépatites Virales, Conselho Nacional de Desenvolvimento Científico e Tecnológico, Shiraz University of Medical Sciences, Fondation de France, Natural Science Foundation of Jiangsu Province, Higher Education Commission, Pakistan, Ministerio de Ciencia e Innovación, Universität Zürich, Russian Science Foundation, Natural Science Foundation of Shaanxi Province, Natural Science Foundation of Shandong Province, Fondation Bettencourt Schueller, Università degli Studi di Udine, Tarbiat Modares University, BioGaia, Junta de Castilla y León, Ministry of Science and ICT, South Korea, JKA Foundation, Iranian National Institute for Oceanography and Atmospheric Science, Medical Research Council Centre for Neurodevelopmental Disorders, National Institutes of Health, National Nuclear Security Administration, College of Veterinary Medicine, Purdue University, Canadian Institutes of Health Research, Social Sciences and Humanities Research Council of Canada, Biotechnology and Biological Sciences Research Council, Australian Research Council, National Health and Medical Research Council, Health Research Council of New Zealand, Japan Society for the Promotion of Science, Science and Engineering Research Board, Japan Science and Technology Agency, European Regional Development Fund, Institute for Information and Communications Technology Promotion, Key Technologies Research and Development Program, National Key Research and Development Program of China, Fundamental Research Funds for the Central Universities, National Major Science and Technology Projects of China, Chinese Academy of Medical Sciences Initiative for Innovative Medicine, Basic and Applied Basic Research Foundation of Guangdong Province, National Institute of General Medical Sciences, National Institute of Neurological Disorders and Stroke, National Institute of Biomedical Imaging and Bioengineering, U.S. National Library of Medicine, National Center for Advancing Translational Sciences, Laboratory Directed Research and Development, H2020 European Research Council, H2020 Future and Emerging Technologies, HORIZON EUROPE European Research Council, CHIST-ERA, Children’s Health Foundation
OpenAlex ID: W4407796286